| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/01/2001 | EP1119620A2 Polynucleotides coding for secreted polypeptides. some having similarity to syncollin or claudin or cytokine. their therapeutic uses |
| 08/01/2001 | EP1119619A2 Nlk1 -interacting proteins |
| 08/01/2001 | EP1119618A2 Stress promoter control of therapeutic genes in gene therapy: compositions and methods |
| 08/01/2001 | EP1119584A1 Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation |
| 08/01/2001 | EP1119580A1 ANTISENSE MODULATION OF EXPRESSION OF TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTORS (TRAFs) |
| 08/01/2001 | EP1119579A1 Antisense modulation of bcl-x expression |
| 08/01/2001 | EP1119573A2 Bipyridine manganese complexes |
| 08/01/2001 | EP1119568A1 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| 08/01/2001 | EP1119567A1 Quinazoline derivatives |
| 08/01/2001 | EP1119565A1 Cytotoxic alkaloids (halitulin) |
| 08/01/2001 | EP1119555A1 Biphenylene lactams as prostaglandin receptor ligands |
| 08/01/2001 | EP1119551A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119548A1 Pyrrole-2,5-diones as gsk-3 inhibitors |
| 08/01/2001 | EP1119542A1 Prostaglandin receptor ligands |
| 08/01/2001 | EP1119538A1 Derivatives of phenantrene for medicinal use and a process for their preparation |
| 08/01/2001 | EP1119376A2 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 08/01/2001 | EP1119371A1 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY |
| 08/01/2001 | EP1119367A1 Method of using fetuin to induce apoptosis in cancer cells |
| 08/01/2001 | EP1119362A1 Method of using tetracycline compounds to enhance interleukin-10 production |
| 08/01/2001 | EP1119361A2 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| 08/01/2001 | EP1119355A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119353A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
| 08/01/2001 | EP1119351A2 Use of catechol derivatives as proteinase inhibitors |
| 08/01/2001 | EP1119252A2 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 08/01/2001 | EP0975350B1 Use of an extract of alchemilla vulgaris |
| 08/01/2001 | EP0885013B1 Use of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses for the preparation of medicaments |
| 08/01/2001 | EP0806963B1 Carcinoma treatment |
| 08/01/2001 | EP0760675B1 Compositions comprising dna damaging agents and p53 |
| 08/01/2001 | EP0748218B1 Plaster-shaped transdermal system with a tamoxifen derivative |
| 08/01/2001 | EP0656946B1 Immunoglobulins devoid of light chains |
| 08/01/2001 | EP0569583B1 Controlled use of polyether-substituted tumor agents in diagnosis and therapy |
| 08/01/2001 | CN1306576A G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 08/01/2001 | CN1306535A Thienopyridine compounds, their prodn. and use |
| 08/01/2001 | CN1306531A Epothilones derivatives, their synthesis and uses |
| 08/01/2001 | CN1306526A Novel heterocyclically substituted amides with cysteine protease-inhibiting effect |
| 08/01/2001 | CN1306515A Combinations of protein farnesyltransferase and HMG COA reductase inhibitors and their use to treat cancer |
| 08/01/2001 | CN1306512A Heterocyclic inhibitors of P38 |
| 08/01/2001 | CN1306509A Substituted benzamides, their prodn. and use as cysteine protease inhibitors |
| 08/01/2001 | CN1306505A Substituted benzamides, their prodn. and use |
| 08/01/2001 | CN1306504A Movel acyl pseudodipeoptides, prepn method and pharmaceutical compsns. contg. same |
| 08/01/2001 | CN1306439A Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
| 08/01/2001 | CN1306433A Use of chemically-stabilized chlorite solution for inhibiting antigen-specific immune response |
| 08/01/2001 | CN1306428A Inhibitors of transcription factor NF-KB |
| 08/01/2001 | CN1306425A Process for synthesizing Cox-2 inhibitors |
| 08/01/2001 | CN1306422A Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for treatment or prevention of diseases characterized by abnormal cell proliferation |
| 08/01/2001 | CN1306008A Conjugate of Lidamycin with active fragment of monoclonal antibody |
| 08/01/2001 | CN1306007A Dry cell factor |
| 08/01/2001 | CN1306003A Oligose with anticancer activity used as medicines or health-care products to improve immunity |
| 08/01/2001 | CN1305847A Conjugate of monoclonal antibody medicine using cyclodextrin as coupling agent |
| 08/01/2001 | CN1305842A Chinese medicine for treating ovarian tumor |
| 08/01/2001 | CN1305834A Chinese medicine for curing cancers |
| 08/01/2001 | CN1069047C Anticancer and antalgesic oral liquid |
| 07/31/2001 | US6268490 Bicyclonucleoside and oligonucleotide analogues |
| 07/31/2001 | US6268488 Active therapeutic agent attached to blocking moiety that is sensitive to catalytic action of molecules having retro-aldol and retro-michael catalytic activity; targeted antitumor, cytotoxic and antibiotic therapy |
| 07/31/2001 | US6268411 Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| 07/31/2001 | US6268394 Contacting a cell with an amount of a sesquiterpene lactone |
| 07/31/2001 | US6268391 Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases |
| 07/31/2001 | US6268379 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 07/31/2001 | US6268376 Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones |
| 07/31/2001 | US6268375 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition |
| 07/31/2001 | US6268374 Uracil reductase inactivators |
| 07/31/2001 | US6268365 Src family SH2 domain inhibitors |
| 07/31/2001 | US6268363 Antitumor |
| 07/31/2001 | US6268361 Estrogen dependent disorders including cancer, enodmetriosis, etc |
| 07/31/2001 | US6268350 Polynucleotides for inhibiting metastasis and tumor cell growth |
| 07/31/2001 | US6268334 Cells include cardiovascular cells, and the peptide may be delivered in a stent to treat or prevent restinosis. |
| 07/31/2001 | US6268163 Identification of drug candidates modulating factor VII-mediated intracellular signaling |
| 07/31/2001 | US6268156 Testing patients being treated with cimetidine for colorectal cancer for sialyl lewis x antigen |
| 07/31/2001 | US6268151 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/31/2001 | US6267994 Use of extract of cimicifuga racemosa |
| 07/31/2001 | US6267960 Administering monoclonal antibody designated atcc no. hb-12612, hb-12616, atcc no. hb12618, or atcc no. hb-12617 which binds specifically to extracellular domain of prostate stem cell antigen (psca) to inhibit growth of prostate tumor |
| 07/31/2001 | CA2237263C Radionuclide labeling of vitamin b12 and coenzymes thereof |
| 07/31/2001 | CA2218372C Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds |
| 07/31/2001 | CA2208639C Camptothecin derivatives and its manufacturing method |
| 07/31/2001 | CA2118119C Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| 07/31/2001 | CA2107553C Monoclonal antibodies to stem cell factor receptors |
| 07/31/2001 | CA2059305C Hexa-cyclic compound |
| 07/26/2001 | WO2001053835A2 Methods for detecting cancer of the central nervous system |
| 07/26/2001 | WO2001053541A1 Antisense modulation of caspase 8 expression |
| 07/26/2001 | WO2001053528A1 Antisense inhibition of ptp1b expression |
| 07/26/2001 | WO2001053506A2 Virus strains for the oncolytic treatment of cancer |
| 07/26/2001 | WO2001053505A2 Herpes virus strains for gene therapy |
| 07/26/2001 | WO2001053486A1 Compositions and methods for the treatment of tumor |
| 07/26/2001 | WO2001053482A1 VITAMIN D3-RESPONSE SEQUENCE LOCATED IN THE 5'-UPSTREAM OF p27/KiP1 GENE AND METHOD FOR SCREENING DRUG BY USING THE SEQUENCE |
| 07/26/2001 | WO2001053469A2 Phosphatases |
| 07/26/2001 | WO2001053468A2 Lipid metabolism enzymes and polynucleotides encoding them |
| 07/26/2001 | WO2001053467A1 Recombinant flaviviruses and methods of use thereof |
| 07/26/2001 | WO2001053351A2 Apoptin bindendes protein |
| 07/26/2001 | WO2001053344A2 Chondromodulin-i related peptide |
| 07/26/2001 | WO2001053343A1 Human polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | WO2001053342A1 Chimeric prostate-homing peptides with pro-apoptotic activity |
| 07/26/2001 | WO2001053341A1 A new polypeptide-human zinc finger protein 13 and the polynucleotide encoding it |
| 07/26/2001 | WO2001053321A2 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers |
| 07/26/2001 | WO2001053317A1 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/26/2001 | WO2001053314A1 Antisense modulation of daxx expression |
| 07/26/2001 | WO2001053313A1 Antisense modulation of smad7 expression |
| 07/26/2001 | WO2001053311A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression |
| 07/26/2001 | WO2001053302A1 5H-QUINOXALINO[2,3-b]NAPHTHO[2,1][1,4]OXAZIN-5-ONE AND INTERMEDIATE FOR THE PREPARATION THEREOF |
| 07/26/2001 | WO2001053299A1 Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof |
| 07/26/2001 | WO2001053297A1 Alpha v integrin receptor antagonists |